Company Profile: BioSante Pharmaceuticals, Inc. (BISP)

BioSante is a development stage biopharmaceutical company that is developing a pipeline of hormone therapy products to treat men and women. The company is also engaged in the development of its proprietary calcium phosphate, nanoparticulate-based platform technology, or CAP, for vaccine adjuvants or immune system booster, drug delivery systems and the purification of the milk of transgenic animals.

The company's hormone therapy products, which it licenses on an exclusive basis from Antares Pharma, Inc., address a variety of hormone therapies for symptoms that affect both men and women. Symptoms addressed by these hormone therapies include impotence, lack of sex drive, muscle weakness and osteoporosis in men and menopausal symptoms in women including hot flashes, vaginal atrophy, decreased libido and osteoporosis.

The products the company in-licenses from Antares are gel formulations of testosterone (the natural male hormone), estradiol (the natural female hormone), a combination of estradiol and testosterone and a combination of estradio and progestogen (another female hormone). The gels are designed to be quickly absorbed through the skin after application on the arms, abdomen or thighs, delivering the required hormone to the bloodstream evenly and in a non-invasive, painless manner. The gels are formulated to be applied once per day and to be absorbed into the skin without a trace of residue.

The company's strategy with respect to its hormone therapy product portfolio is to conduct human clinical trials to obtain approval from the U.S. FDA and market the products in the United States. With regard to its CAP technology, which it licenses on an exclusive basis from the University of California, the company's strategy over the next 12 months is to continue development of its nonparticle technology and actively seek collaborators and licensees to accelerate the development and commercialization of products incorporating the technology.